Loading stock data…
SGHT
$4.45+0.36 (+8.80%)
Market ClosedLast close May 1
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sight Sciences, Inc. in the Healthcare sector is trading at $4.45. The stock is currently 52% below its 52-week high of $9.24, remaining 12.9% below its 200-day moving average. Technical signals show neutral RSI of 69 and bullish MACD crossover, explaining why SGHT maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 69) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.45
Potential Upside
5%
Whystock Fair Value$4.67
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Buy
Mean target$8.34+87.4%
Range$4.35 – $12.00
Fundamentals
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segmen...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$230.61M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.49
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-133.36%
Volume
Today's trading volume
137,410
Recent News
Fuel Tech Leads The Pack Of 3 Noteworthy Penny Stocks
In the last week, the market has stayed flat, but it is up 29% over the past year with earnings expected to grow by 16% per annum over the next few years. In this context, identifying stocks that combine value and growth potential becomes crucial for investors looking to capitalize on these trends. While penny stocks might seem like a relic from earlier market days, they remain relevant due to their affordability and potential for growth when backed by strong financials. Here, we explore...
Arq And 2 Other Promising Penny Stocks
Over the last 7 days, the market has dropped 1.9%, although it is up 15% over the past year, with earnings forecast to grow by 15% annually. While penny stocks might seem like a nod to bygone trading days, they still offer relevant opportunities for growth when tied to companies with strong financials. This article explores three such penny stocks that stand out for their potential and financial robustness in today's market landscape.
Sight Sciences, Inc. Q4 2025 Earnings Call Summary
Moby summary of Sight Sciences, Inc.'s Q4 2025 earnings call
Sight Sciences Inc (SGHT) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ...
Sight Sciences Inc (SGHT) reports a 7% revenue increase and strategic focus on market access, despite cash reserve declines and reimbursement hurdles.
Sight Sciences Q4 Earnings Call Highlights
Sight Sciences (NASDAQ:SGHT) reported fourth-quarter 2025 results highlighting growth in both its interventional glaucoma and interventional dry eye segments, alongside what management described as continued operating expense discipline and cash management. The company also initiated 2026 revenue gu